HOTH News and Press, Hoth Therapeutics Inc. From 08/27/21

3 Penny Stocks to Watch as SPRT Stock Climbs Higher Penny stocks are climbing higher again as SPRT stock shows the meteoric potential of former small-caps. For those unfamiliar, Support.com Inc. ( NASDAQ: SPRT ) is a provider of customer support services. And while this alone is a p...

Hoth Therapeutics' mRNA 'Frameshifting' Therapy HT-KIT for Mast Cell Cancers Reduces Size, Spread - Research Published in Molecular Therapy Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm PR Newswire NEW Y...

CohBar (NASDAQ:CWBR) +62% on Q2 earnings Good Times Restaurant (NASDAQ:GTIM) +32% on Q3 earnings Upstart Holdings (NASDAQ:UPST) +22% on Q2 earnings Mogo (NASDAQ:MOGO) +20% on Q2 earnings fuboTV (NYSE:FUBO) +16% on Q2 earnings Lantern Pharma (N...

Hoth Therapeutics (NASDAQ:HOTH) announces that it has initiated a preclinical study of HT-ALZ for the treatment of Alzheimer's disease. The goal of the study is to determine the effects of HT-ALZ on behavioral and pathological markers of Alzheimer's disease and to determine if HT-ALZ can impr...

Hoth Therapeutics Initiates Preclinical Study of HT-ALZ for Alzheimer's Disease PR Newswire NEW YORK , Aug. 2, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company , announced today that it has ...

Hoth Therapeutics ([[HOTH]]) announces positive confirmatory results from in vivo model of HT-003 assets as potential treatment against acne.The model showed that HT-003 reduces the expression of toll-like receptor 2 ((TLR2)), one of the most critical pathways for acne pathophysiology.Th...

Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment Against Acne PR Newswire NEW YORK , July 13, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmace...

Hoth Therapeutics (HOTH) announces safety results in cohort 1 of its first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.Shares up more than 8% premarket.The interim safety review indicates that BioLexa was wel...

Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis The primary objectives were achieved in cohort one BioLexa was well-tolerated with no treatment related adverse events Ini...

GreenApple78/iStock via Getty Images Hoth Therapeutics ([[HOTH]] -1.2%) has entered into an amendment to a license agreement signed with the U.S. Army Medical Research and Development Command (USAMRDC). Per the original agreement that became effective on December 22, 2020, USAMRDC granted the...